Health ❯ Healthcare ❯ Patient Outcomes

Response Rates

Adverse Events Overall Survival Minimal Residual Disease Complete Response Progression-Free Survival

FDA Grants Accelerated Approval to Sonrotoclax for Relapsed Mantle Cell Lymphoma

The move offers patients who failed BTK inhibitor therapy a new BCL2 option with early signs of durable response.

Inhibrx Combo Shows 44% Response vs 21% With Pembrolizumab Alone in First-Line Head and Neck Cancer

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

Pumitamig Shows High Response in First-Line Small Cell Lung Cancer Phase 2

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2